Based on their experience in the respiratory field, the Pulmocide team identified two significant respiratory infections with substantial unmet treatment need – Respiratory Syncytial Virus (RSV) infection and Aspergillosis. These widely prevalent infections are associated with significant morbidity and are difficult to treat with currently available therapies.
There is no widely available antiviral treatment for seasonal RSV in infants with bronchiolitis. Treatment of Aspergillosis requires systemic therapies (IV or oral) – the use of azoles for Aspergillosis is associated with significant adverse effects and drug interactions.
There is a clear unmet need for simpler, safer and more effective treatment options, and we believe that the development of a new generation of potent inhaled therapies has the potential to transform the outlook for the management of these diseases.
Addressing unmet need
Pulmocide is developing innovative and novel therapies for the treatment of serious lung infections. However, the optimal medicinal chemistry properties for inhaled medicines are poorly understood and differ significantly from those required for oral delivery. In order to meet the target profile, new therapies must meet potency, lung tissue retention, metabolic and physico-chemical requirements for inhaled delivery.